Approaches to the replacement of ethinylestradiol by natural 17β- estradiol in combined oral contraceptives

Experimental and Toxicologic Pathology

Volumn 50, Issue 4-6, 1998, Pages 458-464

  Hoffmann, H ^a   Moore, C ^a   Zimmermann, H ^a   Elger, W ^b   Schwarz, S ^a   Graser, T ^a   Oettel, M ^a  

^a BAYER PHARMA AG   (Germany)

^b EnTec GmbH   (Germany)

Author keywords

17 estradiol; Contraceptives, oral; Dienogest; Estrogen sulfamates; Ethinylestradiol; Oral contraceptives

Indexed keywords

DIENOGEST; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTRADIOL SULFAMATE; ESTRADIOL VALERATE; ESTROGEN DERIVATIVE; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

BREAKTHROUGH BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; ESTROGEN ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; NAUSEA; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; VOMITING;

EID: 0031702441     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(98)80034-1     Document Type: Article

References (59)

1. ANDERSSON KK and KAPPAS A: Hormones and liver function. In: SCHIFF L, SCHIFF ER (eds) Diseases of the liver. JBLippincott company, Philadelphia 1982, pp 167-235.
2. CSEMICZKY G, DIEBENT T, COELINGH BENNINK H J and LANDGREN BM: The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17β-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desoaestrel only for 7 days. Contraception 1996; 54: 333-338.
3. DITTGEN M, FRICKE S, HOFFMANN H, MOORE C, et al.: Kombinationspräparat zur Kontrazeption auf der Basis natürlicher Estrogene 1995. DE 19540253 A1.
4. ELGER W, SCHWARZ S, HEDDEN A, REDDERSEN G and SCHNEIDER B: Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Molec Biol 1995; 55: 395-403.
5. ELSTEIN M and FURNISS HA: Advances in oral hormonal contraception. Zbl Gynäkol 1995; 117: 559-565.
6. HIRVONEN E, ALLONEN H, ANTILLA M, et al.: Oral contraceptive containing natural estradiol for premenopausal women. Maturitas 1995; 21: 27-32.
7. HOFFMANN H, OLTHOFF U, MOORE C, et al.: A novel sequential regime of estradiol with dienogest or desogestrel for oral contraception. XV FIGO Congress (Copenhagen 3-8 Aug 1997).
8. HUMPEL M, TAUBER U, KUHNZ W, et al.: Comparison of serum ethinylestradiol, sex-hormone binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. Horm Res 1990; 33: 35-39.
9. ISHAK K: Hepatotoxicity of oral contraceptives. In: GREGOIRE AT and BLYE RT (eds.) Contraceptive Steroids. Pharmacology and Safety, Plenum Press New York 1983, pp 179-97.
10. JICK H, JICK SS, GUREWICH V, et al.: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
11. KÄAR K, RHEN K and TARKKILA T: Short term effects of desogestrel and ethinylestradiol upon serum proteins in women. Scand J Clin Lab Invest 1984; 44: 623-627.
12. KIVINEN S and SAURE A: Efficacy and tolerability of a combined oral contraceptive containing 17β-estradiol and desogestrel. Eur J Contracept Reprod Health Care 1996; 1: 183.
13. KOVACS L and HOFFMANN H: A new low-dose oral contraception containing ethinylestradiol, estradiol and dienogest: first experience of its clinical use. In: ELSTEIN M (ed.) Extragenital effects of oral contraceptives. The Parthenon Publishing Group, Carnforth 1997, pp 39-44.
14. KOVACS L, ZALANYI S, TEKULICS A and WHO Task Forse on Oral Contraceptives: A randomized, double-blind study of two combined oral contraceptives containing the same progestoaen, but different estrogens. Contraception 1980; 21: 445-459.
15. KRATTENMACHER R, KNAUTHE R, PARCZYK K, et al.: Estrogen action on hepatic synthesis of angiotensinogen and IGF-1: direct and indirect estrogen effects. J Steroid Biochem Molec Biol 1994; 48: 207-214.
16. KUHL H: Ovulationshemmer. Die Bedeutung der Östrogendosis. Geburtsh Frauenheilk 1990; 50: 910-922.
17. KUHL H: Comparative pharmacology of newer progestogens. Drugs 1996; 51: 188-215.
18. KUHL H: Ideal dose of ethinylestradiol. In: ELSTEIN M (ed.) Extragenital effects of oral contraceptives. The Parthenon Publishing Group, Carnforth 1997, pp 27-83.
19. KUHNZ W, GANSAU C and MAHLER M: Pharmacokinetics of estradiol, free and total estrone in young women following single intravenous and oral administration of 17β-estradiol. Drug Res 1993; 43: 966-973.
20. LINDBERG UB, CRONA N, STIGENDAL L, et al.: A comparison between effects of estradiol valerate and low dose ethinylestradiol on hemostasis parameters. Thromb Haemost 1989; 61: 65-69.
21. LOBO RA and CASSIDENTI DL: Pharmacokinetics of oral 17β-estradiol. J Reprod Med 1992; 37: 77-84.
22. LOBO RA and STANCZYK FZ: New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol 1994; 170: 1499-1507.
23. MANDEL FP, GEOLA FL, LU JKH, et al.: Biologic effects of various doses of ethinylestradiol in postmenopausal women. Obstet Gynecol 1982; 59: 673-679.
24. MEADE TW: Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988; 158: 1646-52
25. MEADE TW and HAINES AP: Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg oestrogen. Lancet 1977; 948-951.
26. 15N zur Beurteilung des Leberstoffwechsels bei hormonaler Kontrazeption. Leber Magen Darm 1990; 90: 34-37.
27. MOORE C, WALTER F, MELLINGER U and ZAHRADNIK HP: Multizentrische Studie zu kontrazeptiver Sicherheit, Zyklusbeeinflussung und Verträglichkeit von MP2000 Mikropille-Ein Zwischenbericht. In: TEICHMANN AT (ed.) Dienogest. Präklinik und Klinik eines Gestasens. W de Gruyter 1995, pp 203-212.
28. MOORE C, WALTER F, KLINGER G and CAROL W: Der Einfluß von Dienogest auf die Ovulation junger Frauen und auf weitere ausgewählte endokrinologische Parameter. In: TEICHMANN AT (ed.) Dienogest. Präklinik und Klinik eines Gestagens. W de Gruyter 1995, pp 161-170.
29. OETTEL M, CAROL W, ELGER W, et al.: A 19-norprogestin without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view. Drugs Today 1995; 31: 517-536.
30. R1: Salmonella typhimurium reverse mutation assay with J 995. Final report 15 Dec 1995
31. R2: Chromosome aberration assay in human lymphocytes in vitro with J 995. Final report 30 Jan 1996
32. R3: In vivo micronucleus assay in bone marrow cells of the mouse with J 995. Final report 12 Dec 1995
33. R4: Unscheduled DNA synthesis in primary hepatocytes of female rats in vitro with J 995. Final report 5 Oct 1995
34. R5: J 995: Assessment of effects on cardiovascular function in the anaesthetised rat following intravenous administration. Final report 26 Jul 1996
35. R6: Examination of J 995 for spasmolytic properties in the isolated guinea-pig ileum. Final report 3 Jan 1996
36. R7: Examination of J 995 for oxytocic or tocolytic properties in the isolated rat uterus. Final report 3 Jan 1996
37. R8: Examination of the influence of J 995 on the spontaneous motility of mice following oral administration. Final report 3 Jan 1996
38. R9: Examination of the influence of J 995 on the thiopental narcosis (sleeping-time) in mice following oral administration. Final report 3 Jan 1996
39. R10: Examination of the influence of J 995 on the diuresis and saluresis in Sprague-Dawley rats following oral administration. Final report 3 Jan 1996
40. R11: J 995: Single dose toxicity study in mice treated by oral route. Final report 10 Nov 1995
41. R12: J 995: Single dose toxicity study in rats treated by oral route. Final report 10 Nov 1995
42. R13: J 995: Single dose toxicity study in mice treated by intraperitoneal route. Final report 25 Jan 1996
43. R14: J 995: Single dose toxicity study in rats treated by intraperitoneal route. Final report 25 Jan 1996
44. R15: J 995: 4-week toxicity study in rats by oral route. Final report 21 May 1996
45. R16: J 995: Toxicity study by oral gavage administration to Cynomolgus monkeys for 4 weeks. Final report 18 Jul 1996
46. SABRA A and BONNAR J: Hemostatic system changes induced by 50 μg and 30 μg estrogen / progestogen oral contraceptives. J Reprod Med 1983; 28: 85-91.
47. SCHWARZ S and ELGER W: Estrogen sulfamates, a novel approach to oral contraception and hormone replacement therapy. Drugs Future 1996; 21: 49-61.
48. SCHWARTZ U and HAMMERSTEIN J: The estrogenic potency of various contraceptive steroids as determined by their effects on transcortin-binding capacity 1974; 76: 159-171.
49. SCHLEUSSNER E and MOORE C: Klinische Studie Phase II zur Überprüfung der Ovulationshemmung und Zyklusstabilität bei Einnahme von zwei verschiedenen Dienogest/Estradiolvalerat-Kombinationen. Final Report 04 Febr 1997.
50. SERUP J, Bostofte E, Larsen S, et al.: Natural oestrogens for oral contraception. (Letter). Lancet 1979; 2: 471-472.
51. SPITZER WO: Balanced view of risks of oral contraceptives. Lancet 1997; 350: 1566-1567.
52. SPITZER WO, LEWIS MA, HEINEMANN LAJ, et al.: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-88.
53. SPONA J, FEICHTINGER W, KINDERMANN C, et al.: Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 μg dienogest. Contraception 1997; 56: 185-191.
54. VON SCHOULTZ B, CARLSTROM K, COLLSTE K, et al.: Estrogen therapy and liver function-metabolic effects of oral and perenteral administration. The Prostate 1989; 14: 389-395.
55. WENZL R, COELINGK BENNINK H, VAN BEEK A, et al.: Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17β-estradiol. Fertil Steril 1993; 60: 616-619.
56. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
57. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception, Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-1582.
58. WINKLER UH, SCHINDLER AE, ENDRIKAT J and DÜSTERBERG B: A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containins 20 μg and 30 μg ethinylestradiol. Contraception 1996; 53: 75-84.
59. WINKLER UH, SCHINDLER AE and GILLAIN D: Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: An open, randomized, parallel-group study. Int J Fertil 1995; 40: 260-268.